Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Frequently asked questions
What sector does Rezolute, Inc. (6HV1) operate in?
Rezolute, Inc. belongs to the Other sector and operates in the industry.
What is Rezolute, Inc. (6HV1) current stock price?
As of the latest data, Rezolute, Inc. stock price is €3.40, with a previous close of €3.38. Rezolute, Inc. gained €0.02 in the last trading session, representing a 0.59% increase.
Does Rezolute, Inc. (6HV1) pay dividends?
No. Rezolute, Inc. does not pay a dividend.
When is Rezolute, Inc. (6HV1) next earnings report?
Rezolute, Inc. is expected to release its next earnings report on June 30, 2026.
What is Rezolute, Inc. (6HV1) beta (volatility) score?
Rezolute, Inc. has a beta of 0.612, indicating lower volatility than the overall market.
